Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. [electronic resource]
Producer: 20100319Description: 1131-6 p. digitalISSN:- 1528-0020
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Blotting, Western
- Carbazoles -- therapeutic use
- Cytokines -- metabolism
- Female
- Furans
- Humans
- Janus Kinase 2 -- antagonists & inhibitors
- Male
- Middle Aged
- Neoplasm Staging
- Polycythemia Vera -- complications
- Primary Myelofibrosis -- complications
- Prognosis
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Survival Rate
- Thrombocythemia, Essential -- complications
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.